139 related articles for article (PubMed ID: 15190384)
1. Understanding NSAID-PPI-COX-2 interrelationships.
Singh G
Drugs Today (Barc); 2004 Mar; 40 Suppl A():21-4. PubMed ID: 15190384
[TBL] [Abstract][Full Text] [Related]
2. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
Limmer S; Ittel TH; Wietholtz H
Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426
[TBL] [Abstract][Full Text] [Related]
3. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage.
Singh G; Triadafilopoulos G
Int J Clin Pract; 2005 Oct; 59(10):1210-7. PubMed ID: 16178990
[TBL] [Abstract][Full Text] [Related]
4. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
Lanas A; Ferrandez A
Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
6. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications.
Peura DA
Am J Med; 2004 Sep; 117 Suppl 5A():63S-71S. PubMed ID: 15478855
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
Chen JT; Pucino F; Resman-Targoff BH
J Pain Palliat Care Pharmacother; 2006; 20(4):11-32. PubMed ID: 17182503
[TBL] [Abstract][Full Text] [Related]
8. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
9. Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors.
Lazzaroni M; Porro GB
Drugs; 2009; 69(1):51-69. PubMed ID: 19192936
[TBL] [Abstract][Full Text] [Related]
10. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage.
Scheiman JM
Arthritis Res Ther; 2013; 15 Suppl 3(Suppl 3):S5. PubMed ID: 24267413
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
Laine L
Rev Gastroenterol Disord; 2004; 4 Suppl 4():S33-41. PubMed ID: 15580145
[TBL] [Abstract][Full Text] [Related]
12. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Spiegel BM; Chiou CF; Ofman JJ
Arthritis Rheum; 2005 Apr; 53(2):185-97. PubMed ID: 15818647
[TBL] [Abstract][Full Text] [Related]
13. [Role of Helicobacter pylori in drug-induced gastrointestinal bleeding].
Chaussade S; Abitbol V
Presse Med; 2003 Nov; 32(37 Pt 2):S60-3. PubMed ID: 14763358
[TBL] [Abstract][Full Text] [Related]
14. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
Strand V
Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal injury from NSAID therapy. How to reduce the risk of complications.
Lanas A
Postgrad Med; 2005 Jun; 117(6):23-8, 31. PubMed ID: 16001765
[TBL] [Abstract][Full Text] [Related]
16. Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors.
Kimmey MB; Lanas A
Aliment Pharmacol Ther; 2004 Feb; 19 Suppl 1():60-5. PubMed ID: 14725581
[TBL] [Abstract][Full Text] [Related]
17. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
18. Management of high-risk patients on non-steroidal anti-inflammatory drugs or aspirin.
Chan FK
Drugs; 2006; 66 Suppl 1():23-8; discussion 29-33. PubMed ID: 16869345
[TBL] [Abstract][Full Text] [Related]
19. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole.
Regula J; Butruk E; Dekkers CP; de Boer SY; Raps D; Simon L; Terjung A; Thomas KB; Lühmann R; Fischer R
Am J Gastroenterol; 2006 Aug; 101(8):1747-55. PubMed ID: 16817839
[TBL] [Abstract][Full Text] [Related]
20. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.
Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
